GKL-006Allo not checked

Beijing Gene Key Life Technology Co., Ltd · GKL-006RTU

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
3 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Allogeneic invariant natural killer T (iNKT) cells administered by intravenous infusion once every two weeks for up to 11 doses. Dose escalation from (3.0±0.9)×10\^8 cells/m2 to (9.0±2.7)×10\^8 cells/m2 per the 3+3 dose-escalation design.”In the company’s words, NCT07915544 on ClinicalTrials.gov
Tested for
ARDS (Acute Respiratory Distress Syndrome), Ankylosing Spondylitis, Solid Tumor Malignancies
Main trialPhase 1/2
“This is a Phase I/II, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of GKL-006RTU injection in participants with moderate to severe Acute Respiratory Distress Syndrome (ARDS). The study consists of two parts: Phase I is a single-arm, open-label study. Eligible participants will receive a single intravenous infusion of GKL-006RTU injection (1 bag or 3 bags, containing approximately 5.0±0.5×10\^8 invariant natural killer T (iNKT) cells per bag) in addition to standard background treatment. The primary objective of this phase is to assess the safety…”In the company’s words, NCT07706855 on ClinicalTrials.gov
Other names
Allogeneic iNKT Cell Therapy · GKL-006RTU

Other drugs for ARDS (Acute Respiratory Distress Syndrome)

All 5 drugs for ARDS (Acute Respiratory Distress Syndrome)

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting 30 Dec 2028 Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)
Phase 1Not yet recruiting 30 Mar 2028 A Study of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
Phase 1Not yet recruiting 30 Sep 2028 GKL-006Allo Injection in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow GKL-006Allo

Following is part of Solo: you see every change to GKL-006Allo the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in